Apogee therapeutics
Apogee Therapeutics is a biotechnology company focused on developing innovative biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunology conditions with significant unmet needs.
Apogee therapeutics Overview
Apogee therapeutics Funding Rounds
Round | Date | Amount Raised | Valuation | Investors | Sources |
---|---|---|---|---|---|
IPO | 7/13/2023 | ||||
Series B | 12/7/2022 | ||||
Series A | 6/1/2022 |
Apogee therapeutics Investors
Investor | Investment Rounds | Lead Partner | Initial Investment | Other Notable Investments |
---|---|---|---|---|
Venrock | Series B, Series A | Series B (2022-12-07) | ||
Wellington Management | Series B | Series B (2022-12-07) |
Apogee therapeutics 409a Valuations
Date | Price per share | Est. Valuation | Filling |
---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Apogee therapeutics Filings
Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Latest Apogee therapeutics News
Waypoint Capital Advisors LLC Invests $36.84 Million in Apogee Therapeutics, Inc. (NASDAQ:APGE)
MarketBeatOctober 20, 2024
Apogee Therapeutics (NASDAQ:APGE) Shares Down 4.1% - Should You Sell?
MarketBeatOctober 18, 2024
11,535 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by AQR Capital Management LLC
MarketBeatOctober 16, 2024
Apogee Therapeutics, Inc. (NASDAQ:APGE) Sees Significant Decline in Short Interest
MarketBeatOctober 15, 2024
The Manufacturers Life Insurance Company Has $2.82 Million Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)
MarketBeatOctober 9, 2024
Apogee Therapeutics executive sells over $370k in company stock By Investing.com
Investing.com AustraliaOctober 5, 2024
Apogee Therapeutics executive sells over $370k in company stock
Investing.comOctober 5, 2024
Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc
Yahoo FinanceOctober 4, 2024